EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Controversies in NEN : An ENETS position statement on unresolved clinical scenarios and emerging approaches with somatostatin analogues

Jorge Hernando iD, Wouter W de Herder iD, Adina Croitoru iD, Eva Tiensuu Janson iD, Raj Srirajaskanthan iD, Ivan Borbath iD, Guenter J Krejs, Ana Paula Santos iD, Joerg Schrader, Gregory Kaltsas iD

Journal of Neuroendocrinology · 2026-11 · 38 (11)

DOI: 10.1111/jne.70313 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Neuroendocrinology, online erschienen am 11.11.2026. Verfasst von Jorge Hernando und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Hepatobiliary Pancreatic Cancer and Endocrine Tumours Unit, Vall d'Hebron University Hospital; Neuroendocrine and Endocr…. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Somatostatin. Die Arbeit nennt 79 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Somatostatin analogues (SSAs) are the cornerstone of treatment for patients with neuroendocrine tumours (NETs), with established anti‐secretory activity in functioning NETs and anti‐proliferative activity in grade 1 and 2 (Ki‐67 levels, up to 10%) gastro‐entero‐pancreatic NETs. However, several clinically relevant scenarios regarding their role still remain insufficiently addressed by available guidance, including the following: patient selection for dose‐escalation or interval‐shortening after disease progression, their anti‐proliferative effect in tumours with a > 10% Ki‐67 index, their role in pulmonary carcinoids, Multiple Endocrine Neoplasia (MEN1)‐related pancreatic NETs and uncommon neuroendocrine neoplasms (NENs), their adjuvant use after surgery, and their continuation beyond disease progression, as well as the presence of predictive biomarkers, quality‐of‐life endpoints, and emerging somatostatin receptor (SSTR)‐targeted strategies. This manuscript addresses 10 practical questions regarding SSA use beyond established indications. The available evidence supports dose‐intensification mainly for improved hormonal symptom control and, in selected patients, temporary disease stabilisation, while objective tumour responses remain uncommon. Anti‐proliferative effects may also be observed in some grade 2 NETs with a Ki‐67 index higher than 10%, albeit with diminishing activity in the presence of increasing proliferative activity, whereas it is limited in grade 3 tumours. Evidence in pulmonary carcinoids, MEN1‐related pancreatic NETs, and other uncommon somatostatin receptor (SSTR)‐positive NETs remains heterogeneous, and mostly based on small or non‐randomised studies. In contrast, routine adjuvant treatment after complete tumour resection is not currently supported, although retrospective studies suggest a potential benefit in selected patients with resected pancreatic NETs at high risk of recurrence. Quantitative SSTR imaging, tissue SSTR2 expression and circulating molecular markers are promising tools for patient selection, but none is currently validated for routine predictive use. New formulations and SSTR‐directed agents with receptor‐binding properties distinct from those of conventional SSAs are expected to broaden future treatment options, although their clinical value will require prospective confirmation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsSomatostatinHumans

Stichwörter der Autor:innen

Gastroenteropancreatic neuroendocrine neoplasmsLanreotideOctreotideSomatostatine Analgoues

Substanzen

Somatostatin

Autor:innen und Institutionen

  • Medical Oncology Department, Hepatobiliary Pancreatic Cancer and Endocrine Tumours Unit, Vall d'Hebron University Hospital; Neuroendocrine and Endocrine Tumours Translational Research Program (NET-VHIO), Vall d'Hebron I…
  • ENETS Center of Excellence, Department of Internal Medicine, Section of Endocrinology, Erasmus MC and Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Department of Medical Oncology, Fundeni Clinical Institute, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
  • Department of Medical Sciences, Endocrine Oncology Unit, Uppsala University Uppsala, Sweden and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Department of Gastroenterology, Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Roger Williams Institute of Liver Studies, Kings College Hospital, London, UK.
  • Department of Gastroenterology and Hepatology, Cliniques universitaires Saint-Luc, and Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium.

ORCID-Profile: Jorge Hernando, Wouter W de Herder, Adina Croitoru, Eva Tiensuu Janson, Raj Srirajaskanthan, Ivan Borbath, Ana Paula Santos, Gregory Kaltsas

Zitieren

APA

Hernando, J., de Herder, W. W., Croitoru, A., Janson, E. T., Srirajaskanthan, R., Borbath, I., Krejs, G. J., Santos, A. P., Schrader, J., & Kaltsas, G. (2026). Controversies in NEN : An ENETS position statement on unresolved clinical scenarios and emerging approaches with somatostatin analogues. Journal of Neuroendocrinology, 38(11). https://doi.org/10.1111/jne.70313

Vancouver

Hernando J, de Herder WW, Croitoru A, Janson ET, Srirajaskanthan R, Borbath I, et al. Controversies in NEN : An ENETS position statement on unresolved clinical scenarios and emerging approaches with somatostatin analogues. Journal of Neuroendocrinology. 2026;38(11). doi:10.1111/jne.70313

BibTeX
@article{Hernando2026,
  author = {Hernando, Jorge and de Herder, Wouter W and Croitoru, Adina and Janson, Eva Tiensuu and Srirajaskanthan, Raj and Borbath, Ivan and Krejs, Guenter J and Santos, Ana Paula and Schrader, Joerg and Kaltsas, Gregory},
  title = {Controversies in NEN : An ENETS position statement on unresolved clinical scenarios and emerging approaches with somatostatin analogues},
  journal = {Journal of Neuroendocrinology},
  year = {2026},
  volume = {38},
  number = {11},
  doi = {10.1111/jne.70313}
}
Kostenlos starten →